Repligen Corporation Reports 21.9% Revenue Growth and Net Income Turnaround in Latest Quarter

Repligen Corporation reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $188.8 million for the three months ended September 30, 2025, a 21.9% increase from $154.9 million in the same period last year. For the nine months ended September 30, 2025, revenue was $540.3 million, up 15.7% from $466.9 million in 2024. The growth was primarily driven by strong contributions from the company's Analytics and Filtration product lines, as well as revenue from the recently acquired 908 Devices PAT Portfolio, which added $2.9 million and $6.9 million to quarterly and year-to-date revenues, respectively.

The company also reported a net income of $14.9 million for the third quarter, compared to a net loss of $654,000 in the same period of 2024. For the nine months, net income was $35.6 million, a substantial increase from $8.4 million in the prior year. This turnaround in profitability was attributed to improved gross margins, which rose to 53.2% for the third quarter, up from 50.0% a year earlier, driven by lower excess and obsolete costs and better leverage on fixed overhead.

Repligen's operational metrics showed a positive trend, with total current assets increasing to $1.1 billion as of September 30, 2025, compared to $1.07 billion at the end of 2024. The company’s cash and cash equivalents stood at $748.7 million, slightly down from $757.4 million at the end of the previous fiscal year. The company’s employee headcount has also grown, reflecting its expansion efforts, particularly in R&D and integration activities following recent acquisitions.

Strategically, Repligen completed the acquisition of 908 Devices' PAT Portfolio on March 4, 2025, for $69.9 million, which included facilities and equipment in North Carolina and Germany. This acquisition is expected to enhance Repligen's capabilities in bioprocessing technologies. Additionally, the company continues to integrate its previous acquisition of Tantti Laboratory Inc., which was finalized in December 2024, further strengthening its product offerings in the bioprocessing space.

Looking ahead, Repligen anticipates continued growth driven by its expanding product portfolio and market demand for bioprocessing technologies. The company is focused on leveraging its recent acquisitions to enhance operational efficiencies and product offerings. However, it remains cautious of macroeconomic factors such as inflation and supply chain challenges that could impact future performance. The company expects to maintain its current cash levels to support ongoing operations and potential future investments in growth opportunities.